Comparative Effectiveness of Risperidone Long-Acting Injectable vs First-Generation Antipsychotic Long-Acting Injectables in Schizophrenia: Results From a Nationwide, Retrospective Inception Cohort Study | Zendy

Jimmi Nielsen | Zendy; S. O. W. Jensen | Zendy; Rasmus Blechingberg Friis | Zendy; Jan Brink Valentin | Zendy; Christoph U. Correll | Zendy

Open Access

Comparative Effectiveness of Risperidone Long-Acting Injectable vs First-Generation Antipsychotic Long-Acting Injectables in Schizophrenia: Results From a Nationwide, Retrospective Inception Cohort Study

Author(s) -

Jimmi Nielsen,

S. O. W. Jensen,

Rasmus Blechingberg Friis,

Jan Brink Valentin,

Christoph U. Correll

Publication year - 2014

Publication title -

schizophrenia bulletin

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.823

H-Index - 190

eISSN - 1745-1701

pISSN - 0586-7614

DOI - 10.1093/schbul/sbu128

Subject(s) - risperidone , schizophrenia (object oriented programming) , antipsychotic , medicine , cohort , retrospective cohort study , psychiatry , pediatrics

To compare in a generalizable sample/setting objective outcomes in patients receiving first-generation antipsychotic long-acting injectables (FGA-LAIs) or risperidone-LAI (RIS-LAI).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog